S&P 500   3,095.03 (+0.03%)
DOW   27,769.53 (-0.05%)
QQQ   201.31 (-0.14%)
CGC   15.99 (-13.57%)
BABA   181.62 (-0.47%)
GE   11.30 (+0.09%)
T   38.88 (-0.72%)
F   8.80 (-0.23%)
ACB   3.25 (-8.46%)
DIS   147.73 (-0.67%)
S&P 500   3,095.03 (+0.03%)
DOW   27,769.53 (-0.05%)
QQQ   201.31 (-0.14%)
CGC   15.99 (-13.57%)
BABA   181.62 (-0.47%)
GE   11.30 (+0.09%)
T   38.88 (-0.72%)
F   8.80 (-0.23%)
ACB   3.25 (-8.46%)
DIS   147.73 (-0.67%)
S&P 500   3,095.03 (+0.03%)
DOW   27,769.53 (-0.05%)
QQQ   201.31 (-0.14%)
CGC   15.99 (-13.57%)
BABA   181.62 (-0.47%)
GE   11.30 (+0.09%)
T   38.88 (-0.72%)
F   8.80 (-0.23%)
ACB   3.25 (-8.46%)
DIS   147.73 (-0.67%)
S&P 500   3,095.03 (+0.03%)
DOW   27,769.53 (-0.05%)
QQQ   201.31 (-0.14%)
CGC   15.99 (-13.57%)
BABA   181.62 (-0.47%)
GE   11.30 (+0.09%)
T   38.88 (-0.72%)
F   8.80 (-0.23%)
ACB   3.25 (-8.46%)
DIS   147.73 (-0.67%)
Log in

AbbVie Stock Price, Forecast & Analysis (NYSE:ABBV)

$87.56
+0.90 (+1.04 %)
(As of 11/14/2019 03:05 PM ET)
Today's Range
$85.94
Now: $87.56
$87.74
50-Day Range
$71.96
MA: $77.33
$86.81
52-Week Range
$62.66
Now: $87.56
$94.98
Volume476,065 shs
Average Volume8.04 million shs
Market Capitalization$129.49 billion
P/E Ratio11.07
Dividend Yield5.00%
Beta0.98
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.75 billion
Cash Flow$9.55 per share
Book Value($5.56) per share

Profitability

Net Income$5.69 billion

Miscellaneous

Employees30,000
Outstanding Shares1,478,820,000
Market Cap$129.49 billion
Next Earnings Date1/24/2020 (Estimated)
OptionableOptionable

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.


AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a -- dividend on Monday, September 9th. Stockholders of record on Tuesday, October 15th will be given a dividend of $1.07 per share on Friday, November 15th. This represents a dividend yield of 6.4%. The ex-dividend date is Friday, October 11th. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its board has authorized a stock repurchase program on Thursday, December 13th 2018, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 3.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its stock is undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) issued its quarterly earnings data on Friday, November, 1st. The company reported $2.33 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.29 by $0.04. The firm had revenue of $8.48 billion for the quarter, compared to analyst estimates of $8.37 billion. AbbVie had a net margin of 9.90% and a negative return on equity of 155.96%. The business's revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.14 EPS. View AbbVie's Earnings History.

When is AbbVie's next earnings date?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, January 24th 2020. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY19 earnings guidance on Friday, November, 1st. The company provided earnings per share guidance of $8.90-8.92 for the period, compared to the Thomson Reuters consensus estimate of $8.90.

What price target have analysts set for ABBV?

14 analysts have issued 12-month target prices for AbbVie's stock. Their forecasts range from $66.61 to $90.00. On average, they anticipate AbbVie's share price to reach $83.51 in the next twelve months. This suggests that the stock has a possible downside of 4.3%. View Analyst Price Targets for AbbVie.

What is the consensus analysts' recommendation for AbbVie?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Has AbbVie been receiving favorable news coverage?

Press coverage about ABBV stock has trended somewhat negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AbbVie earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for AbbVie.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

Who are AbbVie's major shareholders?

AbbVie's stock is owned by many different of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.39%), California Public Employees Retirement System (0.24%), Robeco Institutional Asset Management B.V. (0.20%), Rhumbline Advisers (0.16%), Russell Investments Group Ltd. (0.15%) and New York State Teachers Retirement System (0.15%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including State of Tennessee Treasury Department, SG Americas Securities LLC, Artemis Investment Management LLP, Great West Life Assurance Co. Can, State of New Jersey Common Pension Fund D, Sawgrass Asset Management LLC, Mackay Shields LLC and Motco. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Which institutional investors are buying AbbVie stock?

ABBV stock was purchased by a variety of institutional investors in the last quarter, including PGGM Investments, Russell Investments Group Ltd., California Public Employees Retirement System, Miller Howard Investments Inc. NY, River Road Asset Management LLC, Alberta Investment Management Corp, Robeco Institutional Asset Management B.V. and Candriam Luxembourg S.C.A.. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $87.28.

How big of a company is AbbVie?

AbbVie has a market capitalization of $129.07 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

What is AbbVie's official website?

The official website for AbbVie is http://www.abbvie.com/.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (NYSE ABBV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  999 (Vote Outperform)
Underperform Votes:  678 (Vote Underperform)
Total Votes:  1,677
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Featured Article: Channel Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel